Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPA3 | P15088 | 3/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | FOLH1 | Q04609 | 5/20 | 0.55 |
| ▸ | CPA1 | P15085 | 2/20 | 0.53 |
| ▸ | CPB1 | P15086 | 1/20 | 0.53 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.53 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1915237 | 1.00 | CPA3 (0.68) | CPA3CYP1A2FOLH1CPA1CPB1 | |
| SCHEMBL1915616 | 1.00 | CPA3 (0.68) | CPA3CYP1A2FOLH1CPA1CPB1 | |
| SCHEMBL8700502 | 0.86 | CA12 (0.51) | CPA3CYP1A2FOLH1SLC1A1 | |
| SCHEMBL9574107 | 0.83 | CPA1 (0.66) | CPA3CYP1A2FOLH1CPA1CPB1 | |
| SCHEMBL7505398 | 0.83 | CPA1 (0.66) | CPA3CYP1A2FOLH1CPA1CPB1 | |
| SCHEMBL23552019 | 0.82 | ALDH1A1 (0.50) | CPA3 | |
| SCHEMBL12493936 | 0.82 | CYP1A2 (0.61) | CPA3CYP1A2FOLH1CPA1CPB1 | |
| SCHEMBL7933675 | 0.82 | ALDH1A1 (0.50) | CPA3 | |
| SCHEMBL3963424 | 0.81 | CPA3 (1.00) | CPA3CYP1A2FOLH1CPA1CPB1 | |
| SCHEMBL29088272 | 0.81 | CPA3 (1.00) | CPA3CYP1A2FOLH1CPA1CPB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110230477-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERS | EUROSCREEN S.A. (BE) | 2011-09-22 | — | — | US | disclosed |
| EP-2364297-A1 | Compounds, pharmaceutical composition and methods for use in treating metabolic disorders | Euroscreen S.A. (BE) | 2011-09-14 | — | — | EP | disclosed |
| WO-2011076734-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING INFLAMMATORY DISEASES | EUROSCREEN S.A. (BE) | 2011-06-30 | — | — | WO | disclosed |
| WO-2011076732-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING GASTROINTESTINAL DISORDERS | EUROSCREEN S.A. (BE) | 2011-06-30 | — | — | WO | disclosed |
| WO-2010066682-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERS | EUROSCREEN S.A. (BE) | 2010-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230477-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERS | CPT1A, LIPC, PC | CPA3 739/4885CYP1A2 180/4885FOLH1 1012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.